Free Trial
→ This free guide explains options the way they should be taught (From Base Camp Trading) (Ad)tc pixel
NASDAQ:DCTH

Delcath Systems Q3 2026 Earnings Date & Estimates

Delcath Systems logo
$15.36 +0.32 (+2.13%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$15.06 -0.30 (-1.92%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Delcath Systems is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Delcath Systems in Q3 2026

Delcath Systems is expected to post earnings of -$0.10 per share on revenue of $26.00 million. In the same quarter a year earlier Delcath Systems reported $0.02 per share on revenue of $20.56 million. Delcath Systems last reported on August 6, 2026, posting $0.07 per share and beating the -$0.0891 consensus estimate. Delcath Systems has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.10
Expected Revenue
$26.00 million
Prior-Year EPS
$0.02
Prior-Year Revenue
$20.56 million
Expected EPS Growth
-600.0%
Expected Revenue Growth
+26.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.07 (Beat by +$0.1591)
Last Quarter Revenue
$29.13 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Delcath Systems Q3 2026 Earnings FAQ

Delcath Systems (NASDAQ:DCTH) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026, before market opens.

Delcath Systems' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Delcath Systems to post earnings of -$0.10 per share for Q3 2026.

The consensus revenue estimate for Delcath Systems is $26.00 million for Q3 2026.

Delcath Systems Earnings Headlines

Delcath Systems (NASDAQ:DCTH) Rating Lowered to Hold at Zacks Research
October 8 at 6:12 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31099339
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260911809441/en/delcath-systems-inc.-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
 |  Stansberry Research (Ad)
Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost
September 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/delcath-dcth-liver-cancer-device-062417595.html
Delcath Systems Updates Corporate Bylaws and Governance Framework
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/delcath-systems-updates-corporate-bylaws-and-governance-framework?utm_source=marketbeat.com&utm_medium=referral
These two stocks hit fresh 52-week highs today – DCTH clocks best day in nearly 15 months
August 6, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/these-two-stocks-hit-fresh-52-week-highs-today-dcth-clocks-best-day-in-nearly-15-months/ar-AA29yz8r
See More Delcath Systems Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Delcath Systems? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Delcath Systems and other key companies, straight to your email.

About Delcath Systems

Delcath Systems (NASDAQ:DCTH) is a commercial-stage oncology company focused on liver-directed therapies for patients with metastatic cancer. Its technology is designed to deliver high concentrations of chemotherapy directly to the liver while limiting systemic exposure, addressing cancers that are difficult to treat with conventional approaches.

The company’s primary products are HEPZATO (melphalan for injection) and the HEPZATO KIT in the United States, as well as CHEMOSAT in markets outside the United States. The system is used with percutaneous hepatic perfusion, a procedure in which the liver is temporarily isolated from the general bloodstream, treated with chemotherapy, and then the blood is filtered before being returned to the patient.

In the United States, HEPZATO is approved for certain adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Delcath also markets CHEMOSAT in Europe and other international markets for liver-directed treatment of metastatic liver cancers, subject to local regulatory requirements. The company’s products are administered at specialized treatment centers by trained medical professionals.

View Delcath Systems Profile
Earnings Tools